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Abstract 
Background: Tiotropium Respimat
® 
improved lung function in a phase 2 trial in patients with cystic 
fibrosis (CF). We investigated its efficacy and safety in a phase 3 trial, including a pre-specified 
pooled analysis of the phase 2 and 3 trials. 
Methods: 12-week, randomized, double-blind, placebo-controlled trial of tiotropium Respimat
®
 5 µg 
once daily in patients with CF (N=463).  
Results: Co-primary efficacy endpoints showed no statistical difference between tiotropium and 
placebo: percent-predicted forced expiratory volume in 1 s (FEV1) area under the curve from 0–4 
hours (AUC0‒4h) (95% CI): 1.64% (0.27,3.55; p=0.092); percent-predicted trough FEV1 (95% CI) 
1.40% (0.50,3.30; p=0.15). Adverse events were similar in both groups. Pooled phase 2/3 trial results 
showed a treatment difference in favor of tiotropium: percent-predicted FEV1 AUC0‒4h (95% CI): 
2.62% (1.34,3.90). 
Conclusion: Tiotropium was well tolerated in patients with CF; lung function improvements 
compared to placebo were not statistically significant in the phase 3 trial.  
 
Clinical trials 
These studies are registered with clinical trial identifier numbers NCT00737100 and NCT01179347. 
These studies are also registered with the EudraCT number: 2008-001156-43 and 2010-019802-17. 
 
Keywords: Bronchodilator, cystic fibrosis, Respimat, tiotropium  
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1. Introduction 
Respiratory failure secondary to obstruction of pulmonary airways is the cause of death in more than 
90% of people with cystic fibrosis (CF) [1]. Widely used therapy for CF patients includes antibiotics, 
airway clearance techniques and devices, pancreatic enzymes and nutritional supplements, as well as 
drugs such as dornase alfa, hypertonic saline, ibuprofen and inhaled bronchodilators [1]. No 
bronchodilator is currently approved for the treatment of CF, although their use is widespread. Several 
studies have provided evidence for efficacy of inhaled β2 adrenergic receptor agonists in people with 
CF, but the evidence is currently insufficient to recommend them for long-term care [2]. 
 
Tiotropium bromide is a once-daily, long-acting anticholinergic bronchodilator with the potential to 
improve lung function and alleviate symptoms in people with CF. Tiotropium can be delivered via 
Respimat
® Soft Mist™ Inhaler (SMI), proven to be suitable even in children aged <5 years with a 
valved holding chamber (VHC), the AeroChamber Plus
®
 with facemask [3,4]. In a phase 2 trial 
investigating two doses (2.5 and 5 µg once daily), tiotropium Respimat
®
 dose-dependently improved 
lung function [5]. Based on the available efficacy, safety and pharmacokinetic data on the use of 
tiotropium in people with CF, the 5 μg dose was chosen for the current phase 3 study.  
 
The objective of this phase 3 study was to determine the efficacy and safety of tiotropium Respimat
®
 
5 μg versus placebo as add-on to usual maintenance therapy in people with CF. Based on the phase 2 
trial results [5], we hypothesized that treatment with tiotropium for 12 weeks is more effective in 
improving lung function compared with placebo in people with CF of all ages.  
 
2. Methods 
2.1. Phase 3 trial 
2.1.1. Study design  
This 12-week multinational, multicenter, randomized, placebo-controlled, double-blind, parallel-
group, phase 3 trial compared the efficacy and safety of tiotropium Respimat
®
 (5 µg, two 2.5 µg puffs 
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once daily) with placebo. An open-label extension (12‒60 weeks) assessed long-term safety and 
electrocardiogram (ECG) effects of tiotropium (Supplementary Fig. 1). Randomization was stratified 
by age group (Supplementary Fig. 2). The local institutional review board/independent ethics 
committee granted ethical approval. Written informed consent was obtained from each patient or the 
patient’s legal representative. An external data safety monitoring board committee (associated with 
Cystic Fibrosis Foundation Therapeutics, Bethesda, Maryland, USA) monitored safety. 
 
2.1.2. Participants 
Inclusion and exclusion criteria are listed in full in the supplementary materials. Briefly, stable 
participants with a clear diagnosis of cystic fibrosis (children 5–11 years, adolescents ≥12 years and 
adults ≥18 years) were screened for pre-bronchodilator forced expiratory volume in 1 s (FEV1) ≥25% 
of predicted values [6,7] (no upper limit). Children <5 years were included in the safety analyses only. 
Each patient was trained on the inhaler device using a placebo Respimat
®
 (with VHC for patients 
<5 years). Usual CF maintenance therapy was continued during the study.  
 
2.1.3. Endpoints  
Co-primary endpoints were change from baseline (randomization) to 12 weeks in percent-predicted 
FEV1 area under the curve from 0 to 4 h (AUC0‒4h), chosen as a more accurate representation of the 
response over time than individual time points, and trough FEV1 percent-predicted. Secondary 
pulmonary endpoints were changes from baseline to 12 weeks in forced vital capacity (FVC) AUC0‒4h 
percent-predicted, trough FVC percent-predicted and forced expiratory flow (FEF) between 25% and 
75% of FVC (FEF25−75) percent-predicted.  
 
Additional secondary endpoints were change from baseline to 12 weeks in the revised CF 
questionnaire (CFQ-R) [8] and the proportion of patients with ≥1 pulmonary exacerbation during the 
double-blind treatment period as assessed by the Respiratory and Systemic Symptoms Questionnaire 
(RSSQ) method [9,10] after 12 weeks (further details in supplementary methods). 
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Safety and tolerability assessment was based on adverse event (AE) incidence, changes in vital signs, 
physical examination, clinical laboratory tests and ECG substudy results (supplementary methods). 
 
2.1.4. Assessments 
Pulmonary function tests (PFTs), FEV1 and FVC were conducted according to American Thoracic 
Society/European Respiratory Society criteria [11] at screening visit (1 week before start of 
treatment); at weeks 1, 4 and 12 (double-blind part); at weeks 24‒60 (open-label part); and at the end-
of-treatment visit. At weeks 1 and 12 (day 85), PFTs were performed pre-dose (–10 min prior to study 
drug inhalation), at 30 min, and at 1, 2, 3 and 4 h after inhalation of study drug. At week 4 and weeks 
24‒60, PFTs were only carried out 30 min (±10 min) prior to drug administration. At the end of 
treatment, a single PFT was performed. 
 
2.1.5. Statistical analyses 
To assess efficacy, ≥360 patients were required to be randomized to tiotropium 5 µg or placebo in a 
2:1 ratio. Primary analyses were performed in all treated patients who had ≥1 baseline PFT 
measurement and ≥1 post-baseline on-treatment PFT measurement. Change from baseline in the co-
primary efficacy variables (FEV1 AUC0‒4h and trough FEV1) and all secondary endpoints was 
analyzed using a restricted maximum likelihood‒based mixed-effect model with repeated measures 
(MMRM). The MMRM included “treatment,” “visit,” “treatment-by-visit interaction” and “age 
group” (≤11, ≥12 years) as fixed categorical effects, and “baseline measurement” and “baseline-by-
visit interaction” as continuous covariates. Unstructured (co)variance was used to model the within-
patient errors. Superiority of treatment with tiotropium over placebo was tested at the α=0.025 (one-
sided) level.  
 
Sensitivity analyses to confirm the robustness of the primary results included MMRM analysis in 
liters, MMRM analysis with observed cases instead of imputed values (further details in the 
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supplementary material) and analysis of covariance (ANCOVA). For the co-primary endpoints, pre-
specified subgroup analyses by age (≤11, ≥12 years) and concomitant long-acting β2 agonist (LABA) 
use at baseline (yes/no) were performed. Treatment-by-subgroup interactions with interaction test p-
values <0.1 were considered significant. For the analysis of the proportion of patients with ≥1 
pulmonary exacerbation during the double-blind period (RSSQ), logistic regression with “treatment,” 
“age group,” “baseline weight” and “baseline predicted FEV1” as covariates was used. For the CFQ-
R, descriptive statistics were provided.  
 
Safety endpoints were summarized descriptively. Blinding and randomization, sample size and 
handling of missing data are detailed in the supplementary methods. Analyses were implemented 
using Statistical Analysis System software version 9.2 (SAS Institute Inc., Cary, North Carolina, 
USA). 
 
2.2. Pre-specified pooling of phase 2 and 3 trials  
The randomized, double-blind, 12-week clinical phase 2 [5] and 3 trials had identical design, outcome 
measures, and inclusion and exclusion criteria to enable pooling.  
 
The primary analysis model for PFTs for the pooled analysis mirrored the analysis of the individual 
trials, with the addition of trial as a factor in the models. In addition to those pre-specified in the phase 
2 and 3 trials, the following subgroups were pre-specified for the pooled analysis of the co-primary 
endpoints: baseline inhaled antibiotic use, asthma, screening lung function (<80%/≥80% predicted 
FEV1) and sex. Safety and tolerability assessment was based on AE incidence in the pooled 
population. 
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3. Results 
3.1. Phase 3 trial 
The trial, conducted at 99 sites (20 countries) ran from November 11, 2010, to March 7, 2012. Patient 
disposition is summarized in Supplementary Fig. 3. In total, 464 people with CF were randomized and 
463 received treatment (tiotropium, 308; placebo, 155). Mean (standard deviation; SD) age was 19.8 
(12.5) years, ranging from 5 months (0.4 years) to 70.5 years. A total of 441 patients (95% of those 
treated) completed the double-blind treatment period and continued into the open-label active 
treatment phase. Overall, the demographic profile was balanced between the treatment groups and 
baseline characteristics were as expected for a study population with CF (Table 1). 
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Table 1. Patient demographics and characteristics of the study population at baseline.  
 Main study (phase 3) ECG substudy  
(phase 3) 
Pooled phase 2/3 trials 
 Placebo Tiotropium  
5 µg 
Tiotropium  
5 µg 
Placebo Tiotropium  
5 µg 
No. of patients, n (%) 155 (100.0)  308 (100.0) 102 (100.0)  323 484 
Sex 
Male, n (%)  
 
90 (58.1) 
 
169 (54.9)  
 
63 (61.8)  
 
186 (57.6) 
 
263 (54.3) 
Age, years (mean, SD) 20.6 (13.6)  19.3 (12.0) 22.5 (12.3) 20.5 (12.6) 19.8 (11.7) 
Age group, n (%) 
≤11 years 
≥12 years 
<5 years
a
 
5−11 years 
12−17 years 
≥18 years 
 
55 (35.5) 
100 (64.5)  
8 (5.2) 
47 (30.3) 
28 (18.1) 
72 (46.5) 
 
110 (35.7) 
198 (64.3) 
15 (4.9) 
95 (30.8) 
60 (19.5) 
138 (44.8) 
 
24 (23.5) 
78 (76.5) 
1 (1.0) 
23 (22.5) 
18 (17.6) 
60 (58.8) 
 
99 (30.7) 
224 (69.3) 
8 (2.5)  
91 (28.2) 
63 (19.5) 
161 (49.8) 
 
162 (33.5) 
322 (66.5)  
15 (3.1)  
147 (30.4)  
84 (17.4)  
238 (49.2) 
Percent-predicted FEV1, 
(mean, SD)  
77.5 (24.4) 76·1 (22·5)  77.0 (24.0) 76.0 (25) 
≤11 years 
≥12 years 
90.6 (19.6) 
71.3 (24.0) 
89.8 (17.8) 
69.4 (21.5) 
 90.1 (19.5) 
70.1 (23.5) 
88.8 (16.8) 
69.1 (21.8) 
BMI, kg/m
2
 (mean, SD) 19.61 (3.59)  19.48 (3.99) 19.99 (3.29) 20.0 (4.1) 19.7 (4.0) 
Baseline concomitant 
medications, n (%) 
155 (100.0) 308 (100.0) 88 (86.3)   
Inhaled antibiotics 74 (47.7)  113 (36.7) 40 (39.2) 136 (42.1)  168 (34.7) 
SABA 80 (51.6)  150 (48.7) 46 (45.1) 182 (56.3)  260 (53.7) 
ICS 67 (43.2)  138 (44.8) 38 (37.3) 150 (46·4)  214 (44.2) 
LABA 57 (36.8)  115 (37.3) 34 (33.3) 123 (38.1)  173 (35.7) 
a
 Participants <5 years were only included in safety analyses (no pulmonary function tests). 
BMI: body mass index; ECG: electrocardiogram; FEV1: forced expiratory volume in 1 s; ICS: inhaled 
corticosteroid; LABA: long-acting β2 agonist; SABA: short-acting β2 agonist; SD: standard deviation. 
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3.1.1. Co-primary efficacy endpoints 
There was no statistical difference between tiotropium and placebo for either co-primary efficacy 
endpoint (Fig. 1A; tables 2 and 3; change from baseline difference of tiotropium versus placebo in 
percent-predicted FEV1 AUC0‒4h: 1.64%; 95% confidence interval [CI] –0.27 to 3.55; p=0.092, and 
percent-predicted trough FEV1: 1.40%; 95% CI –0.50 to 3.30; p=0.15). 
 
The results of the primary analyses were supported by the results of sensitivity analyses based on 
analyses in liters (tables 2 and 3), ANCOVAs and observed case analyses (Supplementary Table 1). 
 
Assessment by age showed a greater difference in FEV1 AUC0‒4h (percent-predicted) between 
tiotropium and placebo in patients aged ≥12 years (2.58%, 95% CI 0.50 to 4.65) than ≤11 years  
(–0.63%; 95% CI –4.58 to 3.32). An improvement in lung function with placebo was observed, driven 
by results from patients aged ≤11 years (tables 2 and 3).  
 
The difference between tiotropium and placebo for the change in percent-predicted FEV1 AUC0‒4h was 
greater for patients taking concomitant LABA at baseline (3.40%, 95% CI 1.50 to 5.30) than not 
(1.80%, 95% CI 0.38 to 3.21). This was also true for patients with a screening FEV1 of <80% (3.00%, 
95% CI 1.40 to 4.60) compared with those patients with a screening FEV1 of ≥80% (1.11%, 95% CI  
–0.52 to 2.74). 
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Table 2. Adjusted mean (SE) changes in FEV1 AUC0‒4h (percent-predicted) overall—phase 3 trial and pooled phase 2 and 3 trial*, and in patients aged 
≤11 years and ≥12 years treated with tiotropium 5 µg or placebo after 12 weeksa—phase 3 trial.  
  Change from baseline  Treatment effect 
Treatment N
b
 Mean
c
 (SE) Mean
c
 (SE)  95% CI p-Value  
Phase 3 trial: Overall, percent -predicted    
Placebo  146 0.87 (0.80)    
Tiotropium 5 µg  292 2.51 (0.57) 1.64 (0.97) –0.27 to 3.55 0.092 
Phase 3 trial: Overall, L      
Placebo  146 –0.011 (0.022)    
Tiotropium 5 µg 292 0.059 (0.027) 0.070 (0.027) 0.017 to 0.124 0.010 
Pooled phase 2 and 3: Overall, percent-predicted    
Placebo 315 –0.42 (0.51)     
Tiotropium 5 µg 469 2.20 (0.42)  2.62 (0.65) 1.34 to 3.90 <0.001 
     p value of treatment-by-age interaction 
Phase 3 trial: ≤11 years, percent-predicted    
Placebo  
Tiotropium 5 µg  
47 
94 
3.96 (1.64) 
3.33 (1.14) 
 
–0.63 (2.00) 
 
–4.58 to 3.32 
0.26 Phase 3 trial: ≥12 years, percent-predicted   
Placebo  
Tiotropium 5 µg  
100 
198 
–0.71 (0.86) 
1.86 (0.61) 
 
2.58 (1.05) 
 
0.50 to 4.65 
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a Analysis of the FAS study population based on MMRM model. Analysis with imputation on the FAS. Baseline is pre-dose measurement on day 1. 
b This N refers to the number of patients in the FAS. 
c Based on MMRM, with fixed effects of trial (pooled analysis only), treatment, visit, treatment-by-visit interaction, age group (≤11, ≥12 years), baseline, baseline-by-visit 
interaction (and random effect of center for study 205·339 only). Within-patient errors are modeled by unstructured (co)variance matrix. 
AUC0‒4h: area under the curve from 0 to 4 h; CI: confidence interval; FAS: full analysis set; FEV1: forced expiratory volume in 1 s; MMRM: mixed-effect model with 
repeated measures; SE: standard error.
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Table 3. Adjusted mean (SE) changes in trough FEV1 response overall —phase 3 trial and pooled phase 2 and 3 trial*, and in patients aged ≤11 years and 
≥12 years treated with tiotropium 5 µg compared with placebo after 12 weeksa—phase 3 trial. 
  Change from baseline Treatment effect  
Treatment N
b
 Mean
c
 (SE) Mean
c
 (SE)  95% CI p-Value  
Phase 3 trial: Overall, percent-predicted    
Placebo  147 0.72 (0.80)    
Tiotropium 5 µg  293 2.12 (0.58) 1.40 (0.97) –0.50 to 3.30 0.15 
Phase 3 trial: Overall, L    
Placebo  144 –0.024 (0.022)     
Tiotropium 5 µg  287 0.043 (0.016) 0.067 (0.027) 0.015 to 0.119 0.012 
Pooled phase 2 and 3: Overall, percent-predicted    
Placebo 315 –0.34 (0.54)    
Tiotropium 5 µg 469 1.51 (0.45) 1.85 (0.68) 0.53 to 3.18 0.006 
     p-value of treatment-by-age interaction 
Phase 3 trial: ≤11 years, percent-predicted   
 
0.052 
Placebo  
Tiotropium 5 µg  
46 
94 
4.06 (1.64) 
2.81 (1.14) 
 
–1.24 (2.00) 
 
–5.20 to 2.71 
Phase 3 trial: ≥12 years, percent-predicted   
Placebo  
Tiotropium 5 µg  
98 
193 
–1.29 (0.85) 
1.27 (0.61) 
 
2.56 (1.05) 
 
0.49 to 4.62 
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a Analysis of the FAS study group based on MMRM model. Analysis with imputation on the FAS. Baseline is pre-dose measurement on day 1. 
b This N refers to the number of patients in the FAS. 
c Based on MMRM, with fixed effects of trial (pooled analysis only), treatment, visit, treatment-by-visit interaction, age-group (≤11, ≥12 years), baseline, baseline-by-visit 
interaction (and random effect of center for study 205·339 only). Within-patient errors are modeled by unstructured (co)variance matrix. 
CI: confidence interval; FAS: full analysis set; FEV1: forced expiratory volume in 1 s; MMRM: mixed-effect model with repeated measures; SE: standard error. 
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Fig. 1. Adjusted mean FEV1 AUC0‒4h (percent-predicted ± SE) change from baseline by weeks (FAS). 
A. phase 3 trial; B. pooled phase 2 and 3 trials. AUC0‒ 4h, area under the curve from 0 to 4 h; FAS: full 
analysis set; FEV1: forced expiratory volume in 1 s; SE: standard error. 
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3.1.2. Other lung function measures 
Secondary spirometry endpoints results followed those for co-primary endpoints: tiotropium and 
placebo differences in FVC AUC0−4h change from baseline in percent-predicted, 1.09% (95% CI –0.68 
to 2.86; p=0.23), trough FVC, 1.20% (95% CI –0.62 to 3.02; p=0.19) and FEF25−75, 0.86% (95% CI  
–2.59 to 4.32; p=0.62). 
 
3.1.3. Pulmonary exacerbations and quality of life 
Nine percent of patients taking tiotropium and 8% of patients receiving placebo reported ≥1 
pulmonary exacerbation during the double-blind period (RSSQ method); tiotropium versus placebo 
odds ratio [OR] 1.092; 95% CI 0.453 to 2.633; p=0.84. No relevant differences were noted between 
the treatment groups in mean changes from baseline to 12 weeks in CFQ-R domain scores (data not 
shown).  
 
3.1.4. Safety  
During the double-blind period of this study, AEs were reported at a similar frequency in the 
tiotropium and placebo groups (tiotropium, 65%; placebo, 68%; Table 4). The most frequently 
reported AEs were in the system organ classes (SOCs) of infections and infestations and respiratory, 
thoracic and mediastinal disorders, with cough being the most frequently reported AE (tiotropium, 
18%; placebo, 13%; Supplementary Table 2). Drug-related AEs were balanced between treatment 
groups. Serious AEs (SAEs) were reported at a higher frequency in the tiotropium group (tiotropium, 
12%, placebo, 8%). The treatment difference was driven partly by a greater proportion of AEs in the 
infections and infestations SOC (in particular pneumonia) and by a slightly higher percentage of 
individuals with pulmonary exacerbation in the tiotropium group.  
 
No unexpected findings were noted in the results from the open-label treatment period, the entire 
main period and the ECG study (Supplementary Table 3). 
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Table 4. Overall summary of adverse events (treated set)—phase 3 trial. 
 Double-blind period Open-label treatment 
period 
Entire main study ECG substudy 
 Placebo Tiotropium 5 µg Switched to tiotropium 
5 µg 
Tiotropium 5 µg Tiotropium 5 µg 
No. of patients, n (%) 155 (100.0) 308 (100.0) 147 (100.0) 308 (100.0) 102 (100.0) 
Patients with any AE, n (%) 105 (67.7) 200 (64.9) 112 (76.2) 256 (83.1) 53 (52.0) 
Patients with severe AE, n (%) 5 (3.2) 15 (4.9) 10 (6.8) 29 (9.4) 3 (2.9) 
Patients with a study drug-related AE
a
, n (%) 11 (7.1) 27 (8.8) 10 (6.8) 35 (11.4) 4 (3.9) 
Patients with other significant AE
b
, n (%) 3 (1.9) 8 (2.6) 4 (2.7) 12 (3.9) 0 (0.0) 
Patients with AE leading to discontinuation of 
study drug, n (%) 
3 (1.9) 8 (2.6) 5 (3.4) 15 (4.9) 0 (0.0) 
Patients with serious AEs, n (%) 
Fatal, n 
Immediately life-threatening 
Disability/incapacity 
Required hospitalization 
Prolonged hospitalization 
13 (8.4) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
13 (8.4) 
1 (0.6) 
36 (11.7) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
36 (11.7) 
0 (0.0) 
24 (16.3) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
24 (16.3) 
3 (2.0) 
62 (20.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
61 (19.8) 
0 (0.0) 
6 (5.9) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
6 (5.9) 
0 (0.0) 
17 
 
Congenital anomaly 
Other 
0 (0.0) 
0 (0·0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (0.7) 
0 (0.0) 
1 (0.3) 
0 (0.0) 
0 (0.0) 
a 
As assessed by the study investigators. 
b 
As defined by International Conference on Harmonisation E3 guidelines. A patient may have been counted in more than one seriousness criterion.  
AE: adverse event; ECG: electrocardiogram. 
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3.2. Pre-specified pooled phase 2 and phase 3 study results  
Of the 808 patients randomized to tiotropium 5 µg or placebo in the two trials, 807 were included in 
the treated set of the pooled analysis, with an approximate 1:2 ratio of patients aged ≤11 years and 
patients aged ≥12 years (546 patients, 68%). The characteristics of people with CF were comparable 
between the two trials (including mean [SD] age 20.3 [12.1] years, range 0.4–69.7) and well balanced 
between treatment groups (Table 1). 
 
A difference of 2.62% (95% CI 1.34 to 3.90) in favor of tiotropium was observed in the change from 
baseline in percent-predicted FEV1 AUC0‒4h and of 1.85% (95% CI 0.53 to 3.18) in percent-predicted 
trough FEV1 (Fig. 1B, tables 2 and 3). There was also a difference in favor of tiotropium for the 
adjusted mean changes from baseline to week 12 in FEV1 AUC0‒4h in liters (0.085 L; 95% CI 0.050 to 
0.121) and in trough FEV1 (0.064 L; 95% CI 0.028 to 0.100). There were also positive differences in 
FEV1 AUC0‒4h (adjusted means between 1.43–4.65% predicted) in favor of tiotropium 5 µg across all 
subgroups assessed (age, sex, screening lung function, baseline use of LABA, inhaled antibiotics and 
asthma at baseline), although children aged ≤11 years, patients with a FEV1 ≥80% and those not 
taking LABA at baseline seem to derive less benefit from tiotropium treatment (Supplementary Fig. 
4). The unadjusted mean changes from baseline to week 12 for percent predicted FEV1 AUC0−4h in 
patients aged 12 to 17 years and ≥18 years are consistent with those observed for MMRM analysis for 
the ≥12 year subgroup (placebo: -1.58% change from baseline, 95% CI: -2.61 to -0.56; tiotropium 
5µg: 1.41% change from baseline, 95% CI: 0.54 to 2.27; treatment difference: 2.99%, 95% CI: 1.65 to 
4.33), which provides support for using the combined group (≥12 year subgroup) as a representation 
of what occurs in patients aged 12 to 17 years and ≥18 years separately. 
 
A similar proportion of patients in the tiotropium and placebo groups experienced pulmonary 
exacerbations, as assessed by the RSSQ (7.5% versus 8.6%; OR 0.82; 95% CI 0.46 to 1.48). Baseline 
CFQ-R scores were 73 for placebo and 72 for tiotropium. Mean changes in CFQ-R scores from 
baseline to day 85 were 0.6 and –1.5, respectively, for all questionnaires combined. While baseline 
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scores were relatively high, changes within each treatment group were small and no difference 
between treatments was observed. The most frequently reported AEs were of respiratory nature. A 
>2-fold increase compared with placebo was observed in patients taking tiotropium for AEs of nasal 
congestion and productive cough, particularly for those aged ≤11years (Supplementary tables 4 and 
5); however none were reported as SAEs or led to treatment discontinuation. A slightly higher 
incidence of AEs relating to pulmonary exacerbations was observed in patients taking tiotropium 
versus placebo (Supplementary Table 6). In the pooled analysis, the safety and tolerability of 
tiotropium were comparable overall with placebo (supplementary results).  
 
4. Discussion 
In the phase 3 trial, tiotropium was associated with small improvements in spirometry endpoints, but 
statistical significance versus placebo was not reached. A pre-specified pooling of the phase 2 and 3 
trials was performed to enhance the precision of estimates and to evaluate the effects in various 
subgroups of interest; both co-primary endpoints demonstrated improvements in lung function with 
tiotropium versus placebo. No effect was seen in pulmonary exacerbation rates or respiratory 
symptoms quantified by CFQ-R. 
 
The difference in outcomes from the phase 2 [5] and 3 trials were largely driven by the ≤11-year age 
group, though the reasons for this are not clear. The high frequency of patients with >80% FEV1 
predicted at screening in this age group may have reduced the chances of improvements in lung 
function. However, in the phase 3 trial, patients ≤11years in the placebo group showed an 
improvement in percent-predicted FEV1 AUC0‒4h over time, which suggests a learning effect during 
the trial among the younger patients, who were less skilled in performing spirometry. In a recent study 
of inhaled mannitol, a sustained, significant (p<0.001) improvement in FEV1 was seen in the control 
group [12], but the improvement was not significant in another similarly designed study (p=0.059) in 
similar populations [13]. Interestingly, in the pooled analysis, significant improvements in the 
mannitol versus control group in FEV1 occurred in patients aged ≥18 years old but not in younger 
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participants [14]. Furthermore, and similar to the current study, improvements in percent-predicted 
FEV1 were observed in the placebo group in the 6–17-year age group [14], raising the question of 
whether more intense pulmonary function testing should be done as a run-in phase in children and 
adolescents (≤18 years) with CF.  
 
The trial included people with CF of all ages (5 months to 70.5 years) and disease severities; it can 
therefore be considered of clinical relevance. Overall, the broad inclusion criteria for the tiotropium 
trials in CF facilitated patient recruitment but may have limited the chance of showing efficacy in 
improving pulmonary function and symptoms. Subgroup analyses suggest that adolescents and adults 
with CF, those with lower FEV1 and those taking concomitant LABA were more likely to achieve 
greater benefit from long-term treatment with tiotropium. 
 
People with CF use complex and intense medication regimens. In this study, tiotropium was tested on 
top of usual CF maintenance therapy, including bronchodilators such as short-acting β2 agonists, 
LABAs and LABA/inhaled corticosteroid combinations, antibiotics, inhaled antibiotics and 
mucolytics. The magnitude of improvement in pulmonary function in percent-predicted FEV1 AUC0‒
4h observed with tiotropium in people with CF (pooled phase 2/3: 2.62%) was relatively small. It is 
difficult to compare results with those published in the literature since results are presented in terms of 
relative rather than absolute differences and sometimes with absolute changes in lung volume data 
rather than percent-predicted data. In two recent identical trials of mannitol in CF in which FEV1 was 
expressed in the same way as in our trial (difference versus placebo in percent-predicted FEV1 was 
2.4%, 95% CI 0.9 to 3.9 in one trial [12] and 1.9%, 95% CI –0.02 to 3.8 in the other), changes were 
similar in magnitude to those demonstrated for tiotropium [13]. Treatment differences must also be 
considered in light of the study design and short duration of the trials. Patients were already on usual 
standard of care maintenance therapy and no upper limit of percent-predicted FEV1 at baseline was set 
as a criterion for study entry, limiting the room for improvement.  
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The numerical, but not statistically significant, increase in infections reported as AEs seen in the 
phase 3 study was not observed in the phase 2 study; in the pooled analysis, incidence of all AEs in 
the SOC infections favored placebo, whereas SAEs favored tiotropium. Collectively, safety and 
tolerability were comparable between tiotropium and placebo. 
 
5. Conclusion 
Efficacy, based on lung function and RSSQ results, of inhaled tiotropium delivered by the Respimat
®
 
SMI in people with CF as add-on to usual CF maintenance therapy was not established in this phase 3 
trial. In the pooled phase 2 and 3 results, the improvements in lung function with tiotropium were not 
accompanied by clinical effects on the frequency of pulmonary exacerbations or quality of life. 
Subgroup analyses using pooled phase 2 and 3 results suggest that some individuals with CF may 
derive clinical benefit from tiotropium. Tiotropium Respimat
®
 5 µg was well tolerated in people with 
CF and the overall safety profile was consistent with that of tiotropium in chronic obstructive 
pulmonary disease.  
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